| 期 |
栏目 |
标题 |
文件 |
| 编号 1S (2009) |
Articles |
ANTIANGIOGENNYE PREPARATY V LEChENII RAKA MOLOChNOY ZhELEZY |
|
| 编号 1S (2009) |
Articles |
NEOAD\"YuVANTNAYa ENDOKRINOTERAPIYa RAKA MOLOChNOY ZhELEZY |
|
| 编号 18 (2012) |
Articles |
A new approach to the overcoming resistance to hormone therapy of breast cancer |
|
| 编号 18 (2012) |
Articles |
Adjuvant hormonal therapy in perimenopausal women with ER-positive breast cancer |
|
| 编号 8 (2013) |
Articles |
ChETYRE ASPEKTA AD\"YuVANTNOY TARGETNOY TERAPII HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY |
|
| 编号 8 (2013) |
Articles |
ROL' IMMUNOKON\"YuGATOV V TARGETNOY TERAPII ZLOKAChESTVENNYKh OPUKhOLEY |
|
| 编号 17 (2013) |
Articles |
Znachenie molekulyarnykh markerov pri vybore neoad\"yuvantnoy khimioterapii mestno-rasprostranennogo raka molochnoy zhelezy |
|
| 编号 4 (2014) |
Articles |
Rak molochnoy zhelezy i beremennost' |
|
| 编号 8 (2015) |
Articles |
KOMPLEKSNAYa TERAPIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY |
|
| 编号 8 (2016) |
Articles |
NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER |
|
| 编号 17 (2016) |
Articles |
RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER" |
|
| 编号 17 (2016) |
Articles |
TAXANES IN THE TREATMENT OF BREAST CANCER |
|
| 编号 17 (2017) |
Articles |
De-escalation and escalation of treatment of patients with HER2-positive breast cancer |
|
| 编号 17 (2017) |
Articles |
New possibilities of the treatment of breast cancer: microtubule inhibitors |
|
| 编号 7 (2018) |
Articles |
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER |
|
| 编号 12 (2018) |
Articles |
Ways to improve efficiency of endocrino-therapy of breast cancer: new targeted cells, new therapeutic opportunities |
|
| 卷 26, 编号 12 (2019) |
Articles |
Adjuvant and neoadjuvant therapy for (based on the materials of the 16th St. Gallen International Breast Cancer Conference) |
|
| 卷 27, 编号 7 (2020) |
Articles |
Alpelisib for the treatment of HR+HER2-metastatic breast cancer in patients with the PIK3CA mutation: results of the SOLAR-1 study |
|
| 卷 27, 编号 7 (2020) |
Articles |
Treatment of residual breast cancer |
|
| 卷 27, 编号 7 (2020) |
Articles |
Abemacyclib - new options for the treatment of hormone-positive metastatic breast cancer with CDK4/6 inhibitors |
|
| 卷 27, 编号 11 (2020) |
Articles |
Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer |
|
| 卷 27, 编号 11 (2020) |
Articles |
Endocrine resistance in breast cancer treatment |
|
| 卷 28, 编号 7 (2021) |
Articles |
Search for new prognostic and predictive markers of sensitivity to endocrine therapy, chemotherapy and immunotherapy of breast cancer |
|
| 卷 28, 编号 11 (2021) |
Articles |
Ways to improve endocrine therapy in postmenopausal women with ER+/ HER2- breast cancer |
|
| 卷 29, 编号 7 (2022) |
Articles |
Clinical immunology of breast cancer |
|
| 卷 29, 编号 7 (2022) |
Articles |
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer |
|
| 卷 29, 编号 7 (2022) |
Articles |
Treatment of HER2-positive early (minimal) breast cancer |
|
| 卷 29, 编号 11/12 (2022) |
Articles |
The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer |
|
| 卷 29, 编号 11/12 (2022) |
Articles |
Ixabepilone in the treatment of breast cancer |
|
